TUB Stock Overview
Operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €123.40 |
| 52 Week High | €128.60 |
| 52 Week Low | €60.80 |
| Beta | 0.44 |
| 11 Month Change | 11.37% |
| 3 Month Change | 17.75% |
| 1 Year Change | 76.79% |
| 33 Year Change | 39.91% |
| 5 Year Change | 115.73% |
| Change since IPO | 2,102.78% |
Recent News & Updates
Shareholder Returns
| TUB | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 3.9% | -2.9% | 0.8% |
| 1Y | 76.8% | 15.7% | 7.4% |
Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 19.7% over the past year.
Return vs Market: TUB exceeded the Belgian Market which returned 6.3% over the past year.
Price Volatility
| TUB volatility | |
|---|---|
| TUB Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in BE Market | 7.2% |
| 10% least volatile stocks in BE Market | 2.4% |
Stable Share Price: TUB has not had significant price volatility in the past 3 months.
Volatility Over Time: TUB's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| TUB fundamental statistics | |
|---|---|
| Market cap | €5.49b |
| Earnings (TTM) | €90.02m |
| Revenue (TTM) | n/a |
61.0x
P/E Ratio0.0x
P/S RatioIs TUB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.00m |
| Gross Profit | -€2.00m |
| Other Expenses | -€92.02m |
| Earnings | €90.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Aug 02, 2025
| Earnings per share (EPS) | 2.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.6% |
How did TUB perform over the long term?
See historical performance and comparison